Afqlir 40 mg/ml, Injektionslösung in einer Fertigspritze

7680701260014 CH-70126 Injektionslösung

No image available

Article details

Package size
1
Selling units
1
Measure
Fertigspritze(n)
Galenic form
Injektionslösung
Galenic group
Injektion/Infusion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
03/06/2026
Summary of Product Characteristics
Français
03/06/2026
Summary of Product Characteristics
Italien
03/06/2026

Detailed composition

Substance Quantity Type Category
afliberceptum
2.0 MG Substance Wirkstoff (Principe actif)
histidinum
- Substance HNIDK
histidini hydrochloridum monohydricum
- Substance HNIDK
trehalosum dihydricum
- Substance HNIDK
polysorbatum 20
- Substance HNIDK
acidum hydrochloridum
- Substance HNIDK
natrii hydroxidum
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
1.73 UG Substance HBESI

Reimbursement information

Public price
CHF 478.45
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/12/2025

Authorization holder

Sandoz Pharmaceuticals AG

6343 Risch

Authorization information

Swissmedic authorization number
70126
Drug name
Afqlir, Injektionslösung in einer Fertigspritze
Galenic form
LSINJ
ATC Code
S01LA05
Authorization status
Z
Dispensing category
B
First authorization
25/09/2025
Authorization expiration date
24/09/2030
IT Number
11.99.0.
Domain
Human medicine
Field of application
Exsudative (feuchte) altersbezogene Makuladegeneration (wAMD). Makulaödem infolge eines retinalen Zentralvenenverschlusses (CRVO) und retinalen Venenastverschlusses (BRVO). Diabetisches Makulaödem (DME). Behandlung von subfovealen und juxtafovealen choroidalen Neovaskularisationen infolge einer pathologischen Myopie (mCNV).

Package details

Description (FR)
AFQLIR 40 mg/ml sol inj 2 mg 1 pce ser pré
Description (DE)
AFQLIR 40 mg/ml Inj Lös 2 mg 1 Stk Fertspr
Market launch
23/11/2025
Narcotic (BTM)
No
Buy us a coffee Explore the data